KRAS and cholangiocarcinoma: In the K-Ras/NICD CCA model (harboring K-Ras mutant), indeed, treatment with PD901 at the same dose for 3 weeks did not affect tumor cell proliferation, as indicated by the similar Ki-67 indexes in vehicle and PD901 treated CCA samples10.